2024 MSK Cardio-Oncology Symposium — On Demand

Thursday, May 30, 2024, 8:00 AM - Tuesday, September 30, 2025, 11:00 PM

On May 2—3, 2024, an interdisciplinary group of cardiology and oncology experts from Memorial Sloan Kettering Cancer Center and around the world, presented the latest research and contemporary practice strategies in the prevention, early diagnosis, and management of cardiovascular disease in cancer patients and cancer survivors at the 2024 MSK Cardio-Oncology Symposium. We're excited to offer this state-of-the-art, comprehensive, case-based curriculum available for purchase on demand.

Advances in cancer therapeutics have significantly improved cancer survival. With cancer mortality decreasing, cardiovascular disease has emerged as a formidable competing cause of death. Cancer survivors now demonstrate 2-5 times higher mortality risk due to cardiovascular disease than the general population, threatening to limit the gains achieved in cancer survival. In response to the growing concerns about the cardiovascular challenges faced by patients with cancer, the field of Cardio-Oncology has evolved, consisting of experts in both cancer and cardiovascular medicine working to improve the detection, monitoring, and treatment of cardiovascular disease at each stage of the cancer care continuum. The field is rapidly growing to meet the urgent need to improve the cardiovascular health of patients with cancer.

This symposium highlights the most cutting-edge and trending subjects in the rapidly evolving field of Cardio-Oncology, ensuring participants gain insights into the latest advancements shaping the future of cardiovascular care for cancer patients.

Purchase Options

OPTION 1 — Full Symposium: Access to the entire program with recordings of every session, along with PDFs of the presentations. View the brochure from the live symposium to see a complete list of lectures available in this offering.

OPTION 2 — Individual Sessions: Purchase one or more of the individual sessions, which include both a recording of the presentations and panel discussions, along with PDFs of the presentations ($50 per session).

• Radiation Therapy, Electrophysiology in Cardio-Oncology, Cancer Survivorship and Prevention
• Cardio-Oncology: Moving the Field Forward & Special Lecture: How to Train in Cardio-Oncology: Cardio-Oncology Fellowship Programs
• The Future of Clinical Trials & Research Progress 
• Immunotherapy: Evolving Landscape in Diagnosing and Managing Immune-Related Cardiotoxicity
• Prostate Cancer and Cardiovascular Disease
• Lung Cancer: Advances in Treatment and Their Impact on Cardiovascular Health
• Breast Cancer: Best Practice Strategies to Optimize Outcomes
• Cardiovascular Considerations in Hematologic Malignancies
• Amyloidosis and Multiple Myeloma: Contemporary Diagnosis and New Advances in Treatment
• Thrombosis and Hemostasis in Cancer
• Role of Imaging Markers and Biomarkers in Cardio-Oncology: Strategies for Early Detection of Cardiotoxicity
• Coronary Artery Disease in Cardio-Oncology
• Prevention in Cardio-Oncology
• Best Practices in the Management of Cardiovascular Disease in Patients with Cancer

Target Audience

This symposium is intended for cardiologists, internists, hematologists/oncologists, advanced practice providers, nurses, housestaff and other affiliated healthcare professionals who are involved in the care of cancer patients or have an interest in the field of cardio-oncology.

1. Describe contemporary anti-cancer treatments (such as anthracyclines, targeted therapy, immunotherapy, cellular therapy, radiation), outlining their roles in cancer therapy, mechanisms of action, cardiotoxicity profiles, and their impact on the cardiovascular system
2. Determine the strategies for monitoring and managing cardiotoxicity, identifying the evidence and the knowledge gaps
3. Explain the diagnostic and treatment strategies for cardiac amyloidosis including advances in therapy
4. Demonstrate the principles of the permissive cardiotoxicity strategy and how it applies in specific treatment scenarios
5. Summarize the appropriate use of imaging modalities in contemporary Cardio-Oncology, from guidelines to best practices
6. State the late cardiovascular sequelae of cancer treatment and the best approach to managing the cardiovascular health of adult survivors of childhood cancer
7. Illustrate the challenges of managing acute cardiovascular disease in patients during cancer treatment

Upon successful registration, access to the course materials, including instructions for claiming credit, is located under the 'Course Content' tab. This on demand program will be available for purchase until September 30, 2025.

Discounted registration is available for specific groups. If eligible, you will receive further instructions and a promotion code to use during registration. View our Policy on Registration Discounts for more information.

OPTION 1 — Full Symposium

• Physicians (MDs, PhDs, and DOs): $600

• Advanced Practice Providers: $450

• Nurses and Other Healthcare Providers: $400

• Residents, Fellows, and Students: $200

• MSK Employees: Complimentary

OPTION 2 — Individual Sessions

• $50 Per Session

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates each enduring material for the number of AMA PRA Category 1 Credits™ listed. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

• 2024 MSK Cardio-Oncology Symposium — Full On Demand Program: 16.50
• Radiation Therapy, Electrophysiology in Cardio-Oncology, Cancer Survivorship and Prevention: 2.00
• Cardio-Oncology: Moving the Field Forward & Special Lecture: How to Train in Cardio-Oncology: Cardio-Oncology Fellowship Programs: 1.00
• The Future of Clinical Trials & Research Progress: 1.25
• Immunotherapy: Evolving Landscape in Diagnosing and Managing Immune-Related Cardiotoxicity: 1.00
• Prostate Cancer and Cardiovascular Disease: .75
• Lung Cancer: Advances in Treatment and Their Impact on Cardiovascular Health: .75
• Breast Cancer: Best Practice Strategies to Optimize Outcomes: .75
• Cardiovascular Considerations in Hematologic Malignancies: 1.25
• Amyloidosis and Multiple Myeloma: Contemporary Diagnosis and New Advances in Treatment: 1.00
• Thrombosis and Hemostasis in Cancer: 1.00
• Role of Imaging Markers and Biomarkers in Cardio-Oncology: Strategies for Early Detection of Cardiotoxicity: 1.25
• Coronary Artery Disease in Cardio-Oncology: 1.00
• Prevention in Cardio-Oncology: 1.25
• Best Practices in the Management of Cardiovascular Disease in Patients with Cancer: 1.25

MOC/CC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Points will be awarded equivalent to CME points earned. Points will be sent to the board monthly.

• 2024 MSK Cardio-Oncology Symposium — Full On Demand Program: 16.50
• Radiation Therapy, Electrophysiology in Cardio-Oncology, Cancer Survivorship and Prevention: 2.00
• Cardio-Oncology: Moving the Field Forward & Special Lecture: How to Train in Cardio-Oncology: Cardio-Oncology Fellowship Programs: 1.00
• The Future of Clinical Trials & Research Progress: 1.25
• Immunotherapy: Evolving Landscape in Diagnosing and Managing Immune-Related Cardiotoxicity: 1.00
• Prostate Cancer and Cardiovascular Disease: .75
• Lung Cancer: Advances in Treatment and Their Impact on Cardiovascular Health: .75
• Breast Cancer: Best Practice Strategies to Optimize Outcomes: .75
• Cardiovascular Considerations in Hematologic Malignancies: 1.25
• Amyloidosis and Multiple Myeloma: Contemporary Diagnosis and New Advances in Treatment: 1.00
• Thrombosis and Hemostasis in Cancer: 1.00
• Role of Imaging Markers and Biomarkers in Cardio-Oncology: Strategies for Early Detection of Cardiotoxicity: 1.25
• Coronary Artery Disease in Cardio-Oncology: 1.00
• Prevention in Cardio-Oncology: 1.25
• Best Practices in the Management of Cardiovascular Disease in Patients with Cancer: 1.25

Recorded/Review Date: May 2-3, 2024 | Original Release Date: May 17, 2024 | Termination Date: August 31, 2025

Symposium Directors 

Jennifer Liu, MD
Chief, Cardiology Service
Professor of Clinical Medicine
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College

Dipti Gupta, MD, MPH
Associate Attending, Cardiology Service 
Program Director, Cardio-Oncology Clinical Research Fellowship
Memorial Sloan Kettering Cancer Center

 

Symposium Planning Committee 

Carol L. Chen, MD
Vice Chair, Quality Assurance
Attending, Cardiology Service
Memorial Sloan Kettering Cancer Center 

Stephanie Feldman, MD
Attending
Assistant Professor of Medicine, Division of Cardiology
New York Presbyterian/Weill Cornell Medical College

Annie Tsay, MD
Cardio-Oncology Fellow
Memorial Sloan Kettering Cancer Center 

Eileen Vella, PA-C
Advanced Practice Provider Manager
Memorial Sloan Kettering Cancer Center 

Anthony F. Yu, MD, MS
Associate Attending, Cardiology Service 
Associate Professor of Medicine 
Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College 

 

Invited Symposium Faculty 

Daniel Addison, MD
Ohio State University Wexner Medical Center 
Columbus, OH

Ana Barac, MD, PhD
Inova Schar Cancer
Inova Schar Heart and Vascular
Fairfax, VA

Anne Blaes, MD, MS
University of Minnesota
Minneapolis, MN

Stephanie Dixon, MD, MPH
St. Jude Children’s Research Hospital
Memphis, TN

Michael Fradley, MD
University of Pennsylvania
Philadelphia, PA

Parag Goyal, MD
Weill Cornell Medical Center
New York, NY

Robert Harrington, MD
Weill Cornell Medical Center
New York, NY

Joerg Hermann, MD, PhD
Mayo Clinic
Rochester, MN

Kristine Jang, DO
Stony Brook Medical Center
Stony Brook, NY

Sahil Khera, MD
Mount Sinai Medical Center
New York, NY

Ninian Lang, Bsc, MB, ChB, PhD
University of Glasgow
Glasgow, Scotland

Daniel Lenihan, MD
International Cardio Oncology Society
Tampa, FL

Teresa Lopez-Fernandez, MD
La Paz University
Madrid, Spain

Joshua Mitchell, MD, MSCI
Washington University Medical Center
St. Louis, MO

Babak Navi, MD, MS
Weill Cornell Medical Center
New York, NY

Tomas Neilan, MD, MPH
Massachusetts  General Hospital
Boston, MA

Jayant Raikhelkar, MD
Columbia University Irving Medical Center
New York, NY

Marielle Scherrer-Crosbie, MD, PhD
University of Pennsylvania
Philadelphia, PA

Paaladinesh Thavendiranathan, MD, SM, FRCPC, FASE
Peter Munk Cardiac Center, Toronto General Hospital
Toronto, Ontario, Canada

Jonathan Weinsaft, MD
Weill Cornell Medical Center
New York, NY

MSK Symposium Faculty 

Angel T. Chan, MD, PhD
Cardiology

Paul Cohen, MD, PhD
Cardiology

Chau T. Dang, MD, MPH
Breast Oncology

Sergio A. Giralt, MD
Bone Marrow Transplant

Michelle N. Johnson, MD, MPH
Cardiology

Ioanna Kosmidou, MD, PhD
Cardiology

Andrew Laccetti, MD
GU Oncology

Heather J. Landau, MD
Myeloma Service

Avi Leader, MD
Benign Hematology

Eileen P. McAleer, MD
Cardiology

Diana Roth O’Brien, MD, MPH
Radiation Oncology

Michael Postow, MD
Melanoma

Sofia Romero-Velez, PA-C
Advanced Practice Provider 

Wendy L. Schaffer, MD, PhD
Cardiology

Jessica Scott, PhD
Exercise Oncology

Roni Shouval, MD, PhD
Bone Marrow Transplant

Dylana Smith, AGPCNP-BC
Advanced Practice Provider 

Richard M. Steingart, MD
Cardiology

Helena A. Yu, MD
Thoracic Oncology

Jeffrey Zwicker, MD
Benign Hematology

 

View relevant financial relationships as of the program date, May 2—3, 2024. 

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.